论文部分内容阅读
目的:评价原发性肝癌(HCC)根治性切除术后应用辅助化疗的临床疗效。方法:将89例原发性HCC根治术后患者应用随机数字表法随机分为治疗组和对照组。治疗组45例,给予FOLFOX4(奥沙利铂+CF+5-FU)方案辅助化疗。对照组44例,术后给予营养支持及对症治疗。结果:治疗组AFP≥400μg/L的患者中有82.1%降至400μg/L,明显高于对照组的55.6%(P=0.01),治疗组1、2和3年生存率分别为77.8%、64.4%和33.3%,明显高于对照组的54.5%、40.9%和17.5%(P=0.02)。治疗组的1、2和3年复发率低于对照组,但两组差异无统计学意义。辅助化疗的毒副作用主要为胃肠道副反应、骨髓抑制和神经毒性,经对症治疗均可好转。结论:原发性HCC根治术后行FOLFOX4方案辅助化疗能降低复发率,延长生存时间。
Objective: To evaluate the clinical efficacy of adjuvant chemotherapy after radical resection of primary liver cancer (HCC). Methods: Eighty-nine patients with primary HCC after radical operation were randomly divided into treatment group and control group by random number table. In the treatment group, 45 patients were given adjuvant chemotherapy with FOLFOX4 (oxaliplatin + CF + 5-FU). Control group, 44 patients were given nutritional support and symptomatic treatment. Results: In the treatment group, 82.1% of the patients with AFP≥400μg / L were reduced to 400μg / L, which was significantly higher than 55.6% of the control group (P = 0.01). The 1,2 and 3 year survival rates were 77.8% 64.4% and 33.3% respectively, which was significantly higher than that of the control group (54.5%, 40.9% and 17.5%, P = 0.02). The recurrence rates of 1, 2 and 3 years in the treatment group were lower than those in the control group, but there was no significant difference between the two groups. Side effects of adjuvant chemotherapy mainly gastrointestinal side effects, bone marrow suppression and neurotoxicity, the symptomatic treatment can be improved. Conclusion: FOLFOX4 adjuvant chemotherapy after radical HCC can reduce the recurrence rate and extend the survival time.